nabumetone has been researched along with Cholera Infantum in 13 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "Naproxen-treated patients experienced significantly (p < 0." | 6.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "Repeat oral dosing of nabumetone for 1 month maintains anti-inflammatory efficacy in a carrageenan model of paw oedema yet does not cause gastrointestinal damage." | 3.68 | Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac. ( Blower, PR; Gentry, C; Melarange, R; O'Connell, C, 1991) |
| "Naproxen-treated patients experienced significantly (p < 0." | 2.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "Nabumetone is a nonselective NSAID that offers distinct advantages over other agents in this class with regard to GI tolerability." | 2.44 | Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability. ( Bannwarth, B, 2008) |
| "Oxaprozin is an effective, long-acting anti-inflammatory analgesic, but its comparative advantages remain undefined." | 2.39 | A review of selected newer nonsteroidal anti-inflammatory drugs. ( Amadio, P; Cummings, DM, 1994) |
| " In conclusion, acute and chronic dosing of nabumetone at doses up to five times the ID25 did not cause GI damage in rats." | 2.38 | Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies. ( Spangler, RS, 1993) |
| "Nabumetone is a novel nonsteroidal antiinflammatory drug (NSAID) with a unique pharmacologic profile." | 2.38 | The unique pharmacologic profile of nabumetone. ( Blower, PR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hedner, T | 1 |
| Melander, A | 1 |
| Bannwarth, B | 2 |
| Melarange, R | 2 |
| Blower, P | 1 |
| Spangler, R | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Eversmeyer, W | 1 |
| Poland, M | 1 |
| DeLapp, RE | 1 |
| Jensen, CP | 1 |
| Spangler, RS | 1 |
| Becvár, R | 1 |
| Urbanová, Z | 1 |
| Vlasáková, V | 1 |
| Vítová, J | 1 |
| Rybár, I | 1 |
| Maldyk, H | 1 |
| Filipowicz-Sosnowska, A | 1 |
| Bernacka, K | 1 |
| Mackiewicz, S | 1 |
| Gömör, B | 1 |
| Rojkovich, B | 1 |
| Siro, B | 1 |
| Bereczki, J | 1 |
| Toth, K | 1 |
| Sukenik, S | 1 |
| Green, L | 1 |
| Ehrenfeld, M | 1 |
| Pavelka, K | 1 |
| Freston, J | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Blower, PR | 2 |
| Gentry, C | 1 |
| O'Connell, C | 1 |
5 reviews available for nabumetone and Cholera Infantum
| Article | Year |
|---|---|
Safety of the nonselective NSAID nabumetone : focus on gastrointestinal tolerability.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Gastrointestinal Diseases; Humans; Nabu | 2008 |
A review of selected newer nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1994 |
Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dose-Response Relationship, Drug; Etodo | 1993 |
[Gastrointestinal tolerance of nonsteroidal anti-inflammatory agents].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials as Topic; Gastrointestinal Disea | 2000 |
The unique pharmacologic profile of nabumetone.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Gastric Mucosa | 1992 |
2 trials available for nabumetone and Cholera Infantum
| Article | Year |
|---|---|
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dicl | 1999 |
6 other studies available for nabumetone and Cholera Infantum
| Article | Year |
|---|---|
[Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Gastrointestinal Diseas | 2004 |
Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Carrageen | 1994 |
Rofecoxib and the risk of adverse upper gastrointestinal effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase Inhibitors; Gastrointestinal Dise | 2000 |
[Side effects cause enormous costs. Expensive arthritis therapy].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib; | 2001 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carrageenan; Diclofenac; E | 1991 |